Biogen Inc.

BMV:BIIB * Stock Report

Market Cap: Mex$471.2b

Biogen Valuation

Is BIIB * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIIB * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BIIB * (MX$3250) is trading below our estimate of fair value (MX$11540.5)

Significantly Below Fair Value: BIIB * is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIIB *?

Key metric: As BIIB * is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BIIB *. This is calculated by dividing BIIB *'s market cap by their current earnings.
What is BIIB *'s PE Ratio?
PE Ratio14.2x
EarningsUS$1.62b
Market CapUS$23.01b

Price to Earnings Ratio vs Peers

How does BIIB *'s PE Ratio compare to its peers?

The above table shows the PE ratio for BIIB * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average76.2x
A068270 Celltrion
191.2x73.6%₩35.8t
UTHR United Therapeutics
15x8.1%US$16.6b
HZNP Horizon Therapeutics
60.8x16.4%US$26.6b
BMRN BioMarin Pharmaceutical
38x27.3%US$12.2b
BIIB * Biogen
14.2x12.4%Mex$23.0b

Price-To-Earnings vs Peers: BIIB * is good value based on its Price-To-Earnings Ratio (14.2x) compared to the peer average (81.4x).

Price to Earnings Ratio vs Industry

How does BIIB *'s PE Ratio compare vs other companies in the Global Biotechs Industry?

18 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies18PE020406080100+
18 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BIIB * is good value based on its Price-To-Earnings Ratio (14.2x) compared to the Global Biotechs industry average (25.2x).

Price to Earnings Ratio vs Fair Ratio

What is BIIB *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIIB * PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BIIB *'s Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BIIB * forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentMex$3,250.00
Mex$5,063.41
+55.8%
18.8%Mex$6,880.05Mex$3,621.08n/a29
Nov ’25Mex$3,530.00
Mex$5,184.66
+46.9%
17.1%Mex$6,934.60Mex$3,649.79n/a29
Oct ’25Mex$3,880.00
Mex$5,299.24
+36.6%
13.7%Mex$6,707.71Mex$3,726.51n/a30
Sep ’25n/a
Mex$5,298.08
0%
13.0%Mex$6,675.77Mex$3,708.76n/a30
Aug ’25Mex$3,940.00
Mex$5,226.55
+32.7%
13.6%Mex$6,570.24Mex$3,754.42n/a30
Jul ’25Mex$4,250.00
Mex$5,136.42
+20.9%
14.4%Mex$6,349.00Mex$3,628.00n/a30
Jun ’25Mex$3,714.53
Mex$4,829.05
+30.0%
14.2%Mex$5,934.99Mex$3,391.42n/a29
May ’25Mex$3,700.00
Mex$4,870.18
+31.6%
13.4%Mex$5,956.23Mex$3,403.56n/a31
Apr ’25Mex$3,523.00
Mex$5,143.39
+46.0%
12.7%Mex$6,847.20Mex$3,937.14n/a30
Mar ’25Mex$3,762.46
Mex$5,143.39
+36.7%
12.7%Mex$6,847.20Mex$3,937.14n/a30
Feb ’25n/a
Mex$5,390.64
0%
11.1%Mex$6,992.34Mex$4,219.51n/a30
Jan ’25Mex$4,416.53
Mex$5,310.80
+20.2%
10.2%Mex$6,693.51Mex$4,060.28n/a31
Dec ’24Mex$4,017.00
Mex$5,618.31
+39.9%
11.1%Mex$6,953.59Mex$4,218.04n/a29
Nov ’24Mex$4,315.00
Mex$5,892.76
+36.6%
9.2%Mex$7,267.36Mex$4,832.79Mex$3,530.0029
Oct ’24n/a
Mex$5,754.38
0%
10.5%Mex$7,660.48Mex$4,726.30Mex$3,880.0029
Sep ’24n/a
Mex$5,473.99
0%
10.2%Mex$7,321.92Mex$4,517.42n/a28
Aug ’24Mex$4,514.00
Mex$5,612.90
+24.3%
9.7%Mex$7,300.56Mex$4,621.45Mex$3,940.0028
Jul ’24Mex$4,815.00
Mex$5,788.33
+20.2%
8.5%Mex$6,849.62Mex$4,526.26Mex$4,250.0027
Jun ’24Mex$5,300.00
Mex$5,867.39
+10.7%
8.4%Mex$6,986.25Mex$4,616.54Mex$3,714.5327
May ’24Mex$5,010.00
Mex$5,907.14
+17.9%
8.8%Mex$7,135.58Mex$4,715.22Mex$3,700.0027
Apr ’24Mex$4,989.94
Mex$6,042.94
+21.1%
9.7%Mex$7,270.27Mex$4,665.71Mex$3,523.0026
Mar ’24Mex$4,961.50
Mex$5,895.60
+18.8%
9.6%Mex$7,099.78Mex$4,556.30Mex$3,762.4626
Feb ’24n/a
Mex$6,075.45
0%
10.1%Mex$7,545.22Mex$4,673.53n/a26
Jan ’24n/a
Mex$6,342.02
0%
8.9%Mex$7,325.04Mex$4,889.96Mex$4,416.5326
Dec ’23Mex$5,727.69
Mex$6,118.04
+6.8%
9.3%Mex$7,087.61Mex$4,731.46Mex$4,017.0026
Nov ’23n/a
Mex$6,012.29
0%
12.0%Mex$7,296.36Mex$4,298.94Mex$4,315.0026

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV *

US$3,880.00

7D

-11.8%

1Y

12.0%

CSPC Pharmaceutical Group

HK$69.4b

An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.

1093 N

HK$15.69

7D

0%

1Y

-27.0%

Exact Sciences

US$13.1b

Provides cancer screening and diagnostic test products in the United States and internationally.

EXAS *

US$872.00

7D

0%

1Y

n/a